Caprelsa (vandetanib) is a small molecule pharmaceutical. Vandetanib was first approved as Caprelsa on 2011-04-06. It is used to treat thyroid neoplasms in the USA. It has been approved in Europe to treat thyroid neoplasms. The pharmaceutical is active against proto-oncogene tyrosine-protein kinase receptor Ret and vascular endothelial growth factor receptor 2. In addition, it is known to target epidermal growth factor receptor. Caprelsa's patents are valid until 2028-08-08 (FDA).
|Drug Class||Angiogenesis inhibitors|